CIRS develops three new prostate phantoms to consolidate nine previous versions
Oct 31, 2014 (Norfolk, Va.) CIRS today announced the release of their newest prostate phantoms, which combine nine previous versions into three concise designs.
The new CIRS Ultrasound Prostate Training Phantoms are multi-modality disposable phantoms developed for practicing procedures that involve scanning the prostate with a rectal probe, including ultrasound-guided cryosurgery, radioactive seed implantation, and needle biopsy.
Gel formulations within the Model 053S, 053L and 053L-EF are designed to minimize needle tracking and to provide imaging contrast under CT, MRI, ultrasound and elastography.
The phantoms are available with lesions (053L) and without lesions (053S) and can be ordered in either the standard side-fire configuration or an alternate geometry optimized for end-fire probes (053L-EF).
The development of the 053S, 053L and 053L-EF improves upon and consolidates several older versions of CIRS prostate phantoms. Previous orders will be filled, however, no new orders will be accepted for the following CIRS products:
For more information about the Model 053S, 053L and 053L-EF, visit www.cirsinc.com.
CIRS, a Castleray company, is recognized worldwide for tissue simulation technology and is the leader in the manufacture of phantoms and simulators for quantitative densitometry, calibration, quality control and research in the field of medical imaging and radiotherapy. CIRS is headquartered in Norfolk, VA (USA) and distributes products worldwide.
2428 Almeda Avenue, Suite 316
Norfolk, VA 23513